ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

ClinicalTrials.gov ID: NCT06481592

Public ClinicalTrials.gov record NCT06481592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.

Study identification

NCT ID
NCT06481592
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

  • Lifileucel Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
Female
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 28, 2024
Primary completion
Apr 30, 2028
Completion
Oct 31, 2029
Last update posted
Oct 29, 2025

2024 – 2029

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Honor Health Phoenix Arizona 85016 Recruiting
University of Southern California Los Angeles California 90007 Recruiting
Orlando Health Orlando Florida 32806 Recruiting
H. Lee Moffitt Cancer Center and Research Institute, Inc. Tampa Florida 33612 Recruiting
Augusta University Augusta Georgia 30912 Recruiting
UofL Health - Brown Cancer Center Louisville Kentucky 40202 Recruiting
Barbara Ann Karmanos Cancer Hospital Detroit Michigan 48201 Recruiting
Roswell Park Cancer Institute Buffalo New York 14203 Recruiting
University of Oklahoma Oklahoma City Oklahoma 73117 Recruiting
Allegheny Health Pittsburgh Pennsylvania 15524 Recruiting
Avera Medical Group Oncology Sioux Falls South Dakota 57105 Recruiting
MD Anderson Cancer Center - U of Texas Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06481592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 29, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06481592 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →